Table 1 Studies including cycle outcomes of ovarian stimulation protocols in patients undergoing medical oocyte cryopreservation

Cobo et al., 2018 [7]

Retrospective

POC and MOC

6362 patients

● 5289 POC

● 1073 MOC

Antagonist

Agonist

Antagonist+letrozole

POC:

Antagonist: 10.5 ± 7.3^a

Agonist: 8.8 ± 5.9

Antagonist+letrozole: NA

MOC:

Antagonist: 13.4 ± 9.5^a,b

Agonist: 8.3 ± 6.2

Antagonist+letrozole: 11.2 ± 8.1^b

POC:

Antagonist: 8.1 ± 5.8^a

Agonist: 6.5 ± 4.8

Antagonist+letrozole: NA

MOC:

Antagonist: 10.3 ± 7.5^a

Agonist: 5.8 ± 4.6

Antagonist+letrozole: 8.6 ± 6.6

Kawwass et al., 2019 [20]

Meta-analysis

POC and MOC

29,631 cycles

● 2715 MOC

● 13,626 POC

● 6863 other

● 6427 medically indicated

Antagonist

Standard Antagonist

Agonist flare

Mixed/other^b

NA

MOC^c: 81.1% (95% CI 80.1-82.0)

POC (ref)^c: 82.6% (95% CI 80.6-82.7)

Other^c: 82.2% (95% CI 82.2-83.2)

Medical^c: 81.7% (95% CI 80.8-82.6)

Marklund et al., 2020 [21]

Prospective

BrCA patients undergoing MOC or embryo cryopreservation

610 women (380 cycles)

Antagonist

Antagonist+letrozole

Conventional start

Random start

Antagonist+letrozole+GnRHa trigger

Antagonist+letrozole+hCG trigger

Antagonist: 12.21 (range, 0-52)^d

Antag+letrozole: 12.32 (range, 0-55)^d

Conventional: 12.3 (range, 0-55)^d

Random: 12.2 (range, 0-52)^d

GnRHa: 13.66 (range, 0-55)^a,d

hCG: 11.32 (range, 0-44)^a,d

Antagonist: 10 (range, 1-27)

Antag+letrozole: 9.7 (range, 0-40)

Conventional: 10.6 (range, 0-40)

Random: 8.97 (range, 0-24)

GnRHa: 10.4 (range, 0-40)

hCG: 9.1 (range, 0-28)

De Moraes et al., 2019 [22]

Retrospective

POC and MOC

187 patients

● 164 POC

● 23 MOC

Variable (primarily Antagonist)

Per patient:

POC: 13.0 ± 9.1

MOC: 15.6 ± 9.1

Per cycle:

POC: 11.4 ± 8

MOC: 13.8 ± 9

Per patient:

POC: 11.1 ± 8.2

MOC: 12.7 ± 7.1

Per cycle:

POC: 9.7 ± 7

MOC: 11.2 ± 7.2

Pereira et al., 2017 [23]

Retrospective

Cancer patients undergoing MOC or embryo cryopreservation

341 patients

Antagonist

● GnRHa trigger

● hCG trigger

Antagonist+letrozole

● GnRHa trigger

● hCG trigger

Antagonist^c:

● GnRHa trigger: 14.5 ± 11.4

● hCG trigger: 12.5 ± 7.8

Antagonist+letrozole^c:

● GnRHa trigger: 13.1 ± 7.1

● hCG trigger: 13.6 ± 7.5

Antagonist^c:

● GnRHa trigger: 13.3 ± 7.9^a

● hCG trigger: 9.3 ± 6.0^a

Antagonist+letrozole^c:

● GnRHa trigger: 11.8 ± 5.8

● hCG trigger: 9.9 ± 6.0

Quinn et al., 2017 [24]

Retrospective

Patients diagnosed recently with BrCA undergoing POC and MOC

589 patients

● 191 BrCA (with and without letrozole)

● 398 POC

Antagonist

POC: 17.0 ± 0.5^a

BrCA+letrozole: 20.1 ± 1.1^a

BrCA: 16.6 ± 1.2

POC: 13.2 ± −0.4

BrCA+letrozole: 14.1 ± 0.8

BrCA: 12.2 ± 1.0

Schon et al., 2017 [25]

Retrospective

POC and MOC

259 cycles

● 129 POC

● 130 MOC

Agonist^a

Antagonist^a

Flare^a

POC: 10 (range, 6-15)

MOC: 11 (range, 8-18)

POC: 7 (range, 4-13)

MOC: 8 (range, 6-15)

Specchia et al., 2019 [26]

Retrospective

MOC

244 patients (252 cycles)

Antagonist

Antagonist+letrozole

13.5 ± 8.4 (range 0-40) per patient

9.5 ± 6.1 (range 0-24) per patient

Turan et al., 2018 [27]

Meta-analysis

MOC

2543 patients

● 713 MOC

● 1835 healthy

Variable

NS

NA